JP2019194251A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019194251A5 JP2019194251A5 JP2019131603A JP2019131603A JP2019194251A5 JP 2019194251 A5 JP2019194251 A5 JP 2019194251A5 JP 2019131603 A JP2019131603 A JP 2019131603A JP 2019131603 A JP2019131603 A JP 2019131603A JP 2019194251 A5 JP2019194251 A5 JP 2019194251A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- botulinum toxin
- subject
- toxin component
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021183197A JP2022028770A (ja) | 2008-12-31 | 2021-11-10 | 注射用ボツリヌス毒素製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14206308P | 2008-12-31 | 2008-12-31 | |
| US61/142,063 | 2008-12-31 | ||
| JP2018141384A JP6559849B2 (ja) | 2008-12-31 | 2018-07-27 | 注射用ボツリヌス毒素製剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018141384A Division JP6559849B2 (ja) | 2008-12-31 | 2018-07-27 | 注射用ボツリヌス毒素製剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021183197A Division JP2022028770A (ja) | 2008-12-31 | 2021-11-10 | 注射用ボツリヌス毒素製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019194251A JP2019194251A (ja) | 2019-11-07 |
| JP2019194251A5 true JP2019194251A5 (2) | 2020-01-16 |
| JP6976997B2 JP6976997B2 (ja) | 2021-12-08 |
Family
ID=42285690
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011543704A Expired - Fee Related JP5866202B2 (ja) | 2008-12-31 | 2009-12-28 | 注射用ボツリヌス毒素製剤 |
| JP2015027842A Expired - Fee Related JP6145465B2 (ja) | 2008-12-31 | 2015-02-16 | 注射用ボツリヌス毒素製剤 |
| JP2017096249A Pending JP2017178954A (ja) | 2008-12-31 | 2017-05-15 | 注射用ボツリヌス毒素製剤 |
| JP2018141384A Expired - Fee Related JP6559849B2 (ja) | 2008-12-31 | 2018-07-27 | 注射用ボツリヌス毒素製剤 |
| JP2019131603A Active JP6976997B2 (ja) | 2008-12-31 | 2019-07-17 | 注射用ボツリヌス毒素製剤 |
| JP2021183197A Pending JP2022028770A (ja) | 2008-12-31 | 2021-11-10 | 注射用ボツリヌス毒素製剤 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011543704A Expired - Fee Related JP5866202B2 (ja) | 2008-12-31 | 2009-12-28 | 注射用ボツリヌス毒素製剤 |
| JP2015027842A Expired - Fee Related JP6145465B2 (ja) | 2008-12-31 | 2015-02-16 | 注射用ボツリヌス毒素製剤 |
| JP2017096249A Pending JP2017178954A (ja) | 2008-12-31 | 2017-05-15 | 注射用ボツリヌス毒素製剤 |
| JP2018141384A Expired - Fee Related JP6559849B2 (ja) | 2008-12-31 | 2018-07-27 | 注射用ボツリヌス毒素製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021183197A Pending JP2022028770A (ja) | 2008-12-31 | 2021-11-10 | 注射用ボツリヌス毒素製剤 |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US9956435B2 (2) |
| EP (2) | EP3332805B1 (2) |
| JP (6) | JP5866202B2 (2) |
| KR (4) | KR102179926B1 (2) |
| CN (2) | CN107343859A (2) |
| AU (6) | AU2009332947C1 (2) |
| BR (1) | BRPI0923731B1 (2) |
| CA (1) | CA2749757C (2) |
| CO (1) | CO6400199A2 (2) |
| CY (1) | CY1120137T1 (2) |
| DK (2) | DK2379104T3 (2) |
| ES (2) | ES2908616T3 (2) |
| HR (1) | HRP20180739T1 (2) |
| HU (1) | HUE037595T2 (2) |
| IL (3) | IL213668A (2) |
| LT (1) | LT2379104T (2) |
| MX (1) | MX2011007059A (2) |
| NO (1) | NO2379104T3 (2) |
| PL (1) | PL2379104T3 (2) |
| PT (1) | PT2379104T (2) |
| RU (1) | RU2011125775A (2) |
| SG (3) | SG172812A1 (2) |
| SI (1) | SI2379104T1 (2) |
| SM (1) | SMT201800215T1 (2) |
| WO (1) | WO2010078242A1 (2) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9211248B2 (en) * | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| JP2007527431A (ja) | 2004-03-03 | 2007-09-27 | ルバンス セラピュティックス | 局所的診断及び治療用の輸送のための組成物及び方法 |
| ZA200707352B (en) * | 2005-03-03 | 2009-04-29 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| BRPI0720729A2 (pt) * | 2006-12-29 | 2014-04-08 | Revance Therapeutics Inc | Moléculas de transporte que utilizam polipeptídeos hiv-tat de sequência inversa. |
| CA2694046C (en) | 2007-07-26 | 2023-09-12 | Revance Therapeutics, Inc. | Cationic peptides and compositions thereof |
| US9173997B2 (en) | 2007-10-02 | 2015-11-03 | Medimop Medical Projects Ltd. | External drug pump |
| US9345836B2 (en) | 2007-10-02 | 2016-05-24 | Medimop Medical Projects Ltd. | Disengagement resistant telescoping assembly and unidirectional method of assembly for such |
| US9656019B2 (en) | 2007-10-02 | 2017-05-23 | Medimop Medical Projects Ltd. | Apparatuses for securing components of a drug delivery system during transport and methods of using same |
| US10420880B2 (en) | 2007-10-02 | 2019-09-24 | West Pharma. Services IL, Ltd. | Key for securing components of a drug delivery system during assembly and/or transport and methods of using same |
| US7967795B1 (en) | 2010-01-19 | 2011-06-28 | Lamodel Ltd. | Cartridge interface assembly with driving plunger |
| PT2271670E (pt) | 2008-03-14 | 2014-11-28 | Allergan Inc | Ensaio imunobaseado da atividade do serotipo a da toxina botulínica |
| US9393369B2 (en) | 2008-09-15 | 2016-07-19 | Medimop Medical Projects Ltd. | Stabilized pen injector |
| US12097357B2 (en) | 2008-09-15 | 2024-09-24 | West Pharma. Services IL, Ltd. | Stabilized pen injector |
| HUE037595T2 (hu) | 2008-12-31 | 2018-09-28 | Revance Therapeutics Inc | Injektálható botulinum toxin készítmények |
| IL268980B (en) * | 2009-06-25 | 2022-09-01 | Revance Therapeutics Inc | Albumin-free botulinum toxin formulations |
| US8157769B2 (en) | 2009-09-15 | 2012-04-17 | Medimop Medical Projects Ltd. | Cartridge insertion assembly for drug delivery system |
| US10071196B2 (en) | 2012-05-15 | 2018-09-11 | West Pharma. Services IL, Ltd. | Method for selectively powering a battery-operated drug-delivery device and device therefor |
| US10071198B2 (en) | 2012-11-02 | 2018-09-11 | West Pharma. Servicees IL, Ltd. | Adhesive structure for medical device |
| SI2490986T1 (sl) * | 2009-10-21 | 2018-12-31 | Revance Therapeutics, Inc. | Metode in sistemi za prečiščenje nekompleksiranega nevrotoksina botulina |
| US10585098B2 (en) | 2009-11-23 | 2020-03-10 | The Johns Hopkins University | Optimizing diagnostics for galactofuranose containing antigens |
| WO2011063395A2 (en) * | 2009-11-23 | 2011-05-26 | The Johns Hopkins University | Lateral flow device for diagnosing microbial infections |
| US8348898B2 (en) | 2010-01-19 | 2013-01-08 | Medimop Medical Projects Ltd. | Automatic needle for drug pump |
| US9452261B2 (en) * | 2010-05-10 | 2016-09-27 | Medimop Medical Projects Ltd. | Low volume accurate injector |
| KR101134146B1 (ko) * | 2010-05-31 | 2012-04-19 | 메덱스젠 주식회사 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
| LT2661276T (lt) * | 2011-01-07 | 2017-12-11 | Revance Therapeutics, Inc. | Paviršinio naudojimo kompozicija, apimanti botulino toksiną ir dažą |
| USD702834S1 (en) | 2011-03-22 | 2014-04-15 | Medimop Medical Projects Ltd. | Cartridge for use in injection device |
| US9072827B2 (en) | 2012-03-26 | 2015-07-07 | Medimop Medical Projects Ltd. | Fail safe point protector for needle safety flap |
| MX370929B (es) * | 2012-10-28 | 2020-01-08 | Revance Therapeutics Inc | Composiciones y usos de las mismas para el tratamiento seguro de la rinitis. |
| US9421323B2 (en) | 2013-01-03 | 2016-08-23 | Medimop Medical Projects Ltd. | Door and doorstop for portable one use drug delivery apparatus |
| US9011164B2 (en) | 2013-04-30 | 2015-04-21 | Medimop Medical Projects Ltd. | Clip contact for easy installation of printed circuit board PCB |
| RU2535115C1 (ru) | 2013-05-15 | 2014-12-10 | Бости Трейдинг Лтд | Фармацевтический состав, содержащий нейротоксин ботулина |
| GB201312317D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| US9480731B2 (en) | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
| US10107822B2 (en) | 2013-12-16 | 2018-10-23 | The Johns Hopkins University | Interferon-gamma release assays for diagnosis of invasive fungal infections |
| ES2642916T3 (es) * | 2014-06-06 | 2017-11-20 | Galit KLEINER-FISMAN | Toxina botulínica para su uso en el tratamiento de la paratonia |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| DK3174523T3 (da) * | 2014-07-31 | 2020-09-28 | Allergan Inc | Formuleringer af biologiske stoffer til intravesikal instillation |
| WO2016036618A1 (en) * | 2014-09-02 | 2016-03-10 | American Silver, Llc | Botulinum toxin and colloidal silver particles |
| EP3590500B1 (en) | 2014-12-23 | 2025-06-25 | Merz Pharma GmbH & Co. KGaA | Botulinum toxin prefilled container |
| US10293120B2 (en) | 2015-04-10 | 2019-05-21 | West Pharma. Services IL, Ltd. | Redundant injection device status indication |
| CN107427474A (zh) | 2015-04-13 | 2017-12-01 | 株式会社Lg生活健康 | 含有调节神经递质释放的成分的可溶性微针 |
| KR102099326B1 (ko) * | 2015-04-13 | 2020-04-09 | 주식회사 엘지생활건강 | 폴리페놀 전달용 용해성 마이크로니들 |
| US10149943B2 (en) | 2015-05-29 | 2018-12-11 | West Pharma. Services IL, Ltd. | Linear rotation stabilizer for a telescoping syringe stopper driverdriving assembly |
| CN113181477B (zh) | 2015-06-04 | 2023-07-14 | 麦迪麦珀医疗工程有限公司 | 用于药物释放装置的筒插入 |
| US9987432B2 (en) | 2015-09-22 | 2018-06-05 | West Pharma. Services IL, Ltd. | Rotation resistant friction adapter for plunger driver of drug delivery device |
| US10576207B2 (en) | 2015-10-09 | 2020-03-03 | West Pharma. Services IL, Ltd. | Angled syringe patch injector |
| JP7044708B2 (ja) | 2015-10-09 | 2022-03-30 | ウェスト ファーマ サービシーズ イスラエル リミテッド | カスタマイズシリンジの充填方法 |
| EP3368071B1 (en) * | 2015-10-29 | 2022-01-26 | ReVance Therapeutics, Inc. | Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect |
| CN109219456B (zh) | 2016-01-21 | 2020-05-15 | 西医药服务以色列有限公司 | 自动注射器中的力牵制 |
| CN113041432B (zh) | 2016-01-21 | 2023-04-07 | 西医药服务以色列有限公司 | 包括视觉指示物的药剂输送装置 |
| WO2017127215A1 (en) | 2016-01-21 | 2017-07-27 | Medimop Medical Projects Ltd. | Needle insertion and retraction mechanism |
| US20170209553A1 (en) * | 2016-01-22 | 2017-07-27 | Transderm, Inc. | Delivery of botulinum with microneedle arrays |
| US11389597B2 (en) | 2016-03-16 | 2022-07-19 | West Pharma. Services IL, Ltd. | Staged telescopic screw assembly having different visual indicators |
| US11103652B2 (en) | 2016-06-02 | 2021-08-31 | West Pharma. Services IL, Ltd. | Three position needle retraction |
| US11730892B2 (en) | 2016-08-01 | 2023-08-22 | West Pharma. Services IL, Ltd. | Partial door closure prevention spring |
| US11338090B2 (en) | 2016-08-01 | 2022-05-24 | West Pharma. Services IL, Ltd. | Anti-rotation cartridge pin |
| KR102480965B1 (ko) | 2016-09-13 | 2022-12-26 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
| MX2019005833A (es) * | 2016-11-21 | 2019-10-30 | Eirion Therapeutics Inc | Administracion transdermica de agentes grandes. |
| AU2018222745B2 (en) * | 2017-02-17 | 2021-02-18 | Allergan, Inc. | Microneedle array with active ingredient |
| EP3600221A4 (en) * | 2017-03-22 | 2021-01-13 | Bonti, Inc. | BOTULINARY NEUROTOXINS FOR USE IN THERAPY |
| CN107185042B (zh) * | 2017-04-29 | 2020-09-01 | 杭州维多利亚医疗美容医院有限公司 | 一种美容注射剂及其制备方法 |
| EP3624819A4 (en) * | 2017-05-18 | 2021-03-24 | Revance Therapeutics, Inc. | Methods of treatment for cervical dystonia |
| EP3630226B1 (en) | 2017-05-30 | 2025-10-22 | West Pharma. Services Il, Ltd. | Modular drive train for wearable injector |
| WO2019046311A1 (en) | 2017-08-28 | 2019-03-07 | Revance Therapeutics, Inc. | TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS |
| KR20190038292A (ko) * | 2017-09-29 | 2019-04-08 | 한국프라임제약주식회사 | 효능 지속시간이 연장된 보툴리눔 독소 조성물 |
| CA3081596A1 (en) * | 2017-11-03 | 2019-05-09 | Revance Therapeutics, Inc. | Botulinum toxin formulations and methods of use thereof in plantar fasciitis with extended duration of effect |
| WO2019113133A1 (en) * | 2017-12-04 | 2019-06-13 | Revance Therapeutics, Inc. | Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration |
| JP7402799B2 (ja) | 2017-12-22 | 2023-12-21 | ウェスト ファーマ サービシーズ イスラエル リミテッド | サイズの異なるカートリッジを利用可能な注射器 |
| KR102088104B1 (ko) | 2018-06-29 | 2020-03-11 | 호서대학교 산학협력단 | 개망초 꽃 에센셜 오일을 포함하는 신경 근육 관련 질환 예방 및 치료용 조성물 |
| MX2021006102A (es) | 2018-12-03 | 2021-09-21 | Eirion Therapeutics Inc | Suministro mejorado de agentes grandes. |
| US20220296503A1 (en) | 2019-05-14 | 2022-09-22 | Eirion Therapeutics, Inc. | Delaying peak effect and/or extending duration of response |
| MX2021014486A (es) | 2020-03-31 | 2022-01-04 | Obi Pharma Inc | Complejo de la toxina tipo a de clostridium botulinum, formulacion y uso del mismo. |
| CN115397399B (zh) * | 2020-04-08 | 2025-06-27 | 玫帝托克斯股份有限公司 | 一种易于控制排出速度且稳定的肉毒杆菌毒素预填充式注射器剂型 |
| CN115916236B (zh) | 2020-06-12 | 2025-08-15 | 凯尔格恩有限公司 | 包含五肽作为活性成分的组合物 |
| KR102940220B1 (ko) * | 2021-02-08 | 2026-03-17 | 주식회사 대웅 | 장기 저장이 가능한 보툴리눔 독소 동결건조 제형 조성물 |
| EP4537850A1 (en) * | 2022-06-10 | 2025-04-16 | Medytox Inc. | Composition for stabilizing botulinum neurotoxin, botulinum neurotoxin formulation containing same, and polypeptides for use therein |
| KR102714765B1 (ko) * | 2023-05-04 | 2024-10-11 | 주식회사 파마리서치바이오 | Dna 단편 혼합물 및 보툴리눔 독소를 포함하는 보툴리눔 독소의 생체 내 지속성이 증가된 지속성 제제 |
| WO2025064729A1 (en) | 2023-09-19 | 2025-03-27 | Revance Therapeutics, Inc. | Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance |
| WO2025229073A1 (en) * | 2024-05-01 | 2025-11-06 | Fastox Pharma Sa | Aqueous compositions of dantrolene |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| US5877278A (en) | 1992-09-24 | 1999-03-02 | Chiron Corporation | Synthesis of N-substituted oligomers |
| CA2124690C (en) | 1992-10-02 | 2007-09-11 | Thomas Osterberg | Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer |
| DE69428813T2 (de) | 1993-12-28 | 2002-04-04 | Allergan Sales Inc | Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz |
| US5756468A (en) | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
| US5512547A (en) | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US6444209B1 (en) | 1996-10-28 | 2002-09-03 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
| US20030095927A1 (en) | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
| EP1053014A4 (en) | 1998-01-26 | 2004-11-10 | Univ Massachusetts | BIOLOGICALLY ACTIVE HEMAGGLUTININE TYPE A i (STRIDIUM BOTULINUM) AND METHOD FOR ITS USE |
| TW574036B (en) | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
| US6358917B1 (en) | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
| US6544548B1 (en) * | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
| US6844324B1 (en) | 1999-11-12 | 2005-01-18 | Massachusetts Institute Of Technology | Modular peptide mediated intracellular delivery system and uses therefore |
| IL149778A0 (en) | 1999-11-22 | 2002-11-10 | Universal Preservation Technologies Inc | Preservation of sensitive biological material |
| US7780967B2 (en) | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
| DK1398038T4 (da) | 2000-02-08 | 2011-03-28 | Allergan Inc | Lægemidler med botulinustoxin |
| US20030118598A1 (en) | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| US6670322B2 (en) * | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
| US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
| US20040033241A1 (en) | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
| US20030215412A1 (en) * | 2000-07-21 | 2003-11-20 | Essentia Biosystems, Inc. | Induction of hair growth with vascular endothelial growth factor |
| JP5610659B2 (ja) | 2000-07-21 | 2014-10-22 | ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 多成分生物学的輸送システム |
| US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
| US6787517B1 (en) | 2000-12-29 | 2004-09-07 | Allergan, Inc. | Agent and methods for treating pain |
| WO2003000193A2 (en) | 2001-06-21 | 2003-01-03 | Surromed, Inc. | Covalent coupling of botulinum toxin with polyethylene glycol |
| CN101721362B (zh) | 2002-02-14 | 2018-07-03 | 中外制药株式会社 | 包含抗体的溶液制剂 |
| US7691394B2 (en) | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
| US20030224020A1 (en) | 2002-05-31 | 2003-12-04 | Zabudkin Alexander F. | Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use |
| US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
| RU2206337C1 (ru) | 2002-10-29 | 2003-06-20 | Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" | Лекарственный препарат для лечения мышечных дистоний и способ его получения |
| US20040086532A1 (en) | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
| DE10333317A1 (de) | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
| US20060210614A1 (en) | 2003-12-26 | 2006-09-21 | Nastech Pharmaceutical Company Inc. | Method of treatment of a metabolic disease using intranasal administration of exendin peptide |
| US20100266638A1 (en) | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
| JP2007527431A (ja) | 2004-03-03 | 2007-09-27 | ルバンス セラピュティックス | 局所的診断及び治療用の輸送のための組成物及び方法 |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| BRPI0508410B8 (pt) * | 2004-03-03 | 2021-05-25 | Revance Therapeutics Inc | composições e métodos para a aplicação tópica e liberação transdérmica de toxinas botulínicas |
| GB2416122A (en) | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
| EP2266599B1 (en) | 2004-07-26 | 2014-04-16 | Merz Pharma GmbH & Co. KGaA | Therapeutic composition with a botulinum neurotoxin |
| US20070196364A1 (en) | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
| WO2006013370A1 (en) | 2004-08-04 | 2006-02-09 | Ipsen Limited | Pharmaceutical composition containing botulinum neurotoxin a2 |
| GB2419526A (en) | 2004-10-28 | 2006-05-03 | Ipsen Ltd | Pharmaceutical composition containing botulinum neurotoxin |
| EP3210620A1 (en) | 2004-08-04 | 2017-08-30 | Ipsen Biopharm Limited | Pharmaceutical composition containing botulinum neurotoxin a2 |
| US7727537B2 (en) | 2005-02-14 | 2010-06-01 | Dpm Therapeutics Corp. | Stabilized compositions for topical administration and methods of making same |
| US7838011B2 (en) | 2005-02-14 | 2010-11-23 | Pankaj Modi | Stabilized protein compositions for topical administration and methods of making same |
| ZA200707352B (en) * | 2005-03-03 | 2009-04-29 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| ES2509872T3 (es) * | 2005-03-03 | 2014-10-20 | Allergan, Inc. | Procedimientos para obtener una toxina clostrídica |
| MX2007010674A (es) * | 2005-03-03 | 2007-11-08 | Revance Therapeutics Inc | Composiciones y metodos para la aplicacion topica y el suministro transdermico de un oligopeptido. |
| CN101228187A (zh) | 2005-03-25 | 2008-07-23 | 特拉维夫大学拉莫特有限公司 | 针对突变p53的共同表位的人合成单链抗体及其用途 |
| US8323666B2 (en) | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
| US8137677B2 (en) | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
| CN103126971A (zh) | 2005-11-17 | 2013-06-05 | 雷文斯治疗公司 | 减少非毒素蛋白质的肉毒杆菌毒素组合物和其局部施用及透皮递送方法 |
| US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
| FR2910327B1 (fr) | 2006-12-22 | 2013-04-26 | Scras | Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida. |
| CN102988995A (zh) * | 2006-12-29 | 2013-03-27 | 雷文斯治疗公司 | 用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法 |
| RU2009149604A (ru) | 2007-06-01 | 2011-07-20 | Мерц Фарма Гмбх Унд Ко. Кгаа (De) | Способ предоставления устойчивого к температуре миорелаксанта на основе нейротоксичного компонента ботулинического токсина в твердой форме |
| CA2694046C (en) * | 2007-07-26 | 2023-09-12 | Revance Therapeutics, Inc. | Cationic peptides and compositions thereof |
| WO2009056651A1 (en) | 2007-11-02 | 2009-05-07 | Cytos Biotechnology Ag | Angiotensin-carrier formulation |
| US9107815B2 (en) | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
| KR20090120222A (ko) | 2008-05-19 | 2009-11-24 | (주)메디톡스 | 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법 |
| US20100196445A1 (en) * | 2008-11-12 | 2010-08-05 | David Nathaniel E | Systems and methods for delivery of biologically active agents |
| CN105833254A (zh) | 2008-12-10 | 2016-08-10 | 阿勒根公司 | 梭菌毒素药物组合物 |
| HUE037595T2 (hu) * | 2008-12-31 | 2018-09-28 | Revance Therapeutics Inc | Injektálható botulinum toxin készítmények |
| EP2248518B1 (en) | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
| IL268980B (en) | 2009-06-25 | 2022-09-01 | Revance Therapeutics Inc | Albumin-free botulinum toxin formulations |
| SI2490986T1 (sl) | 2009-10-21 | 2018-12-31 | Revance Therapeutics, Inc. | Metode in sistemi za prečiščenje nekompleksiranega nevrotoksina botulina |
| US20110106021A1 (en) | 2009-10-30 | 2011-05-05 | Revance Therapeutics, Inc. | Device and Method for Topical Application of Therapeutics or Cosmetic Compositions |
| WO2012048854A2 (en) | 2010-10-12 | 2012-04-19 | Merz Pharma Gmbh & Co. Kgaa | Formulation suitable for stabilizing proteins, which is free of mammalian excipients |
| LT2661276T (lt) | 2011-01-07 | 2017-12-11 | Revance Therapeutics, Inc. | Paviršinio naudojimo kompozicija, apimanti botulino toksiną ir dažą |
| PL3241547T3 (pl) | 2011-03-31 | 2021-02-08 | Medy-Tox Inc. | Liofilizowany preparat toksyny botulinowej |
| US20130224268A1 (en) | 2012-02-27 | 2013-08-29 | Newgen Biopharma Corp. | Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same |
| EP3590500B1 (en) | 2014-12-23 | 2025-06-25 | Merz Pharma GmbH & Co. KGaA | Botulinum toxin prefilled container |
| PL3463432T3 (pl) | 2016-05-27 | 2021-04-19 | Ipsen Biopharm Limited | Ciekła formulacja neurotoksyny stabilizowana tryptofanem lub tyrozyną |
-
2009
- 2009-12-28 HU HUE09837072A patent/HUE037595T2/hu unknown
- 2009-12-28 KR KR1020197021987A patent/KR102179926B1/ko active Active
- 2009-12-28 KR KR1020177017577A patent/KR102005930B1/ko active Active
- 2009-12-28 ES ES18150826T patent/ES2908616T3/es active Active
- 2009-12-28 US US13/141,935 patent/US9956435B2/en active Active
- 2009-12-28 US US12/647,677 patent/US20100168023A1/en not_active Abandoned
- 2009-12-28 PT PT98370729T patent/PT2379104T/pt unknown
- 2009-12-28 SG SG2011047909A patent/SG172812A1/en unknown
- 2009-12-28 CA CA2749757A patent/CA2749757C/en active Active
- 2009-12-28 SG SG10202100698QA patent/SG10202100698QA/en unknown
- 2009-12-28 SI SI200931821T patent/SI2379104T1/en unknown
- 2009-12-28 BR BRPI0923731-3A patent/BRPI0923731B1/pt active IP Right Grant
- 2009-12-28 NO NO09837072A patent/NO2379104T3/no unknown
- 2009-12-28 ES ES09837072.9T patent/ES2669020T3/es active Active
- 2009-12-28 SG SG10201405582YA patent/SG10201405582YA/en unknown
- 2009-12-28 PL PL09837072T patent/PL2379104T3/pl unknown
- 2009-12-28 LT LTEP09837072.9T patent/LT2379104T/lt unknown
- 2009-12-28 WO PCT/US2009/069576 patent/WO2010078242A1/en not_active Ceased
- 2009-12-28 KR KR1020117017761A patent/KR101753242B1/ko active Active
- 2009-12-28 RU RU2011125775/15A patent/RU2011125775A/ru not_active Application Discontinuation
- 2009-12-28 EP EP18150826.8A patent/EP3332805B1/en active Active
- 2009-12-28 JP JP2011543704A patent/JP5866202B2/ja not_active Expired - Fee Related
- 2009-12-28 DK DK09837072.9T patent/DK2379104T3/en active
- 2009-12-28 HR HRP20180739TT patent/HRP20180739T1/hr unknown
- 2009-12-28 MX MX2011007059A patent/MX2011007059A/es active IP Right Grant
- 2009-12-28 SM SM20180215T patent/SMT201800215T1/it unknown
- 2009-12-28 AU AU2009332947A patent/AU2009332947C1/en active Active
- 2009-12-28 EP EP09837072.9A patent/EP2379104B1/en active Active
- 2009-12-28 CN CN201710199742.5A patent/CN107343859A/zh active Pending
- 2009-12-28 KR KR1020207032582A patent/KR102363878B1/ko active Active
- 2009-12-28 CN CN2009801555495A patent/CN102300584A/zh active Pending
- 2009-12-28 DK DK18150826.8T patent/DK3332805T3/da active
-
2011
- 2011-06-20 IL IL213668A patent/IL213668A/en active IP Right Grant
- 2011-07-28 CO CO11094674A patent/CO6400199A2/es not_active Application Discontinuation
-
2015
- 2015-02-16 JP JP2015027842A patent/JP6145465B2/ja not_active Expired - Fee Related
-
2016
- 2016-10-07 AU AU2016238949A patent/AU2016238949C1/en active Active
-
2017
- 2017-05-15 JP JP2017096249A patent/JP2017178954A/ja active Pending
- 2017-09-18 IL IL254558A patent/IL254558B/en active IP Right Grant
-
2018
- 2018-03-27 US US15/937,388 patent/US20180214717A1/en not_active Abandoned
- 2018-04-17 CY CY20181100406T patent/CY1120137T1/el unknown
- 2018-07-27 JP JP2018141384A patent/JP6559849B2/ja not_active Expired - Fee Related
- 2018-10-26 AU AU2018253620A patent/AU2018253620B2/en active Active
-
2019
- 2019-07-17 JP JP2019131603A patent/JP6976997B2/ja active Active
- 2019-10-17 US US16/656,115 patent/US11471708B2/en active Active
-
2021
- 2021-01-29 AU AU2021200561A patent/AU2021200561B2/en active Active
- 2021-03-21 IL IL281675A patent/IL281675A/en unknown
- 2021-11-10 JP JP2021183197A patent/JP2022028770A/ja active Pending
-
2022
- 2022-09-23 US US17/951,220 patent/US20240058628A1/en active Pending
-
2023
- 2023-09-14 AU AU2023229550A patent/AU2023229550B2/en active Active
-
2025
- 2025-12-08 AU AU2025275321A patent/AU2025275321A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019194251A5 (2) | ||
| JP2018522563A5 (2) | ||
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| FI4206216T3 (fi) | Adenoassosioituneen viruksen kapsidimuunnoksia ja menetelmiä niiden käyttämiseksi | |
| RU2018114907A (ru) | Композиция и способ для лечения заболевания, опосредованного комплементом | |
| JP2011530599A5 (2) | ||
| RU2020121540A (ru) | Инъецируемые составы ботулинического токсина и способы их применения с высокими показателями ответа и длительной продолжительностью эффекта | |
| CN101803492A (zh) | 原核苯丙氨酸氨裂合酶的组合物及利用其组合物治疗癌症的方法 | |
| JP2016506727A5 (2) | ||
| JPH02504279A (ja) | インスリン様成長因子１（ｉｇｆ‐１）または因子２（ｉｇｆ‐２）の類縁ペプチド | |
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| JP2016514132A5 (2) | ||
| RU2012106150A (ru) | Вариантные формы уратоксидазы и их применение | |
| FI3534939T3 (fi) | Rokote sian parvovirusta ja sian hedelmättömyyttä ja respiratorista oireyhtymää aiheuttamaa virusta vastaan ja menetelmän sen valmistamiseksi | |
| JP2017529326A5 (2) | ||
| RU2013126581A (ru) | Мутанты стрептокиназы и их ковалентно модифицированные формы | |
| JP2006506942A5 (2) | ||
| JP2015510393A5 (2) | ||
| CN109414426A (zh) | 使用精氨酸耗竭剂的组合癌症免疫疗法 | |
| RU2016152151A (ru) | Препарат, содержащий фактор viii и пептиды фактора фон виллебранда | |
| JP2023500248A5 (2) | ||
| US7147849B2 (en) | Pharmaceutical formulation | |
| JP2024518826A5 (2) | ||
| RU2012157399A (ru) | Пептиды в качестве активных агентов для стабилизации биологических барьеров | |
| RU2017128077A (ru) | Составы, содержащие пептиды, ингибирующие мк2 |